Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F23%3A10472211" target="_blank" >RIV/00064203:_____/23:10472211 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11130/23:10472211
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=N4Ld9UZMZJ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=N4Ld9UZMZJ</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijcha.2023.101317" target="_blank" >10.1016/j.ijcha.2023.101317</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation
Popis výsledku v původním jazyce
Background: The use of beta-blockers in hypertrophic obstructive cardiomyopathy (HOCM) patients after alcohol septal ablation (ASA) lacks data support. We aimed to evaluate the effect of metoprolol on exercise capacity, hemodynamic and laboratory parameters, and quality of life in HOCM patients after ASA. Methods: This was a prospective randomized single-center open-label crossover trial in 21 HOCM patients after ASA. Patients received metoprolol and no beta-blocker for two periods of three months. The endpoints were: peak oxygen uptake (pVO2), maximal left ventricular outflow tract (LVOT) pressure gradient at peak exercise, a ratio of mitral peak velocity of the early filling (E) to early diastolic mitral annular velocity (e') (E/e') at rest, Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) plasmatic concentration. Results: No significant association was found between the treatment and any of the endpoints in the assessed patients: 1) pVO2 (19.5 +- 5.3 ml/kg/min vs. 19.4 +- 4.1 ml/kg/min, p = 0.90), 2) exercise-induced pressure gradient in LVOT 32 +- 37 mmHg vs. 32 +- 30 mmHg, p = 0.84, 3) E/e' ratio at rest (11 +- 4 vs. 10 +- 4, p = 0.23), 4) KCCQ overall summary score (78 +- 11 vs. 77 te +- 15, p = 0.56), 5) NT-proBNP (215 pg/ml [121-333] vs. 153 pg/ml [102-228], p = 0.19). Conclusions: In HOCM patients after successful ASA, metoprolol treatment did not improve exercise capacity, hemodynamic and laboratory parameters, or quality of life.
Název v anglickém jazyce
Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation
Popis výsledku anglicky
Background: The use of beta-blockers in hypertrophic obstructive cardiomyopathy (HOCM) patients after alcohol septal ablation (ASA) lacks data support. We aimed to evaluate the effect of metoprolol on exercise capacity, hemodynamic and laboratory parameters, and quality of life in HOCM patients after ASA. Methods: This was a prospective randomized single-center open-label crossover trial in 21 HOCM patients after ASA. Patients received metoprolol and no beta-blocker for two periods of three months. The endpoints were: peak oxygen uptake (pVO2), maximal left ventricular outflow tract (LVOT) pressure gradient at peak exercise, a ratio of mitral peak velocity of the early filling (E) to early diastolic mitral annular velocity (e') (E/e') at rest, Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) plasmatic concentration. Results: No significant association was found between the treatment and any of the endpoints in the assessed patients: 1) pVO2 (19.5 +- 5.3 ml/kg/min vs. 19.4 +- 4.1 ml/kg/min, p = 0.90), 2) exercise-induced pressure gradient in LVOT 32 +- 37 mmHg vs. 32 +- 30 mmHg, p = 0.84, 3) E/e' ratio at rest (11 +- 4 vs. 10 +- 4, p = 0.23), 4) KCCQ overall summary score (78 +- 11 vs. 77 te +- 15, p = 0.56), 5) NT-proBNP (215 pg/ml [121-333] vs. 153 pg/ml [102-228], p = 0.19). Conclusions: In HOCM patients after successful ASA, metoprolol treatment did not improve exercise capacity, hemodynamic and laboratory parameters, or quality of life.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30201 - Cardiac and Cardiovascular systems
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2023
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
International Journal of Cardiology. Heart & Vasculature
ISSN
2352-9067
e-ISSN
—
Svazek periodika
49
Číslo periodika v rámci svazku
December
Stát vydavatele periodika
NL - Nizozemsko
Počet stran výsledku
6
Strana od-do
101317
Kód UT WoS článku
001131540800001
EID výsledku v databázi Scopus
2-s2.0-85178573911